Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

Truvada PrEP Linked to Rare Case of Serious Kidney Disorder

Researchers in Southern California have identified the first known case of Fanconi syndrome, a type of serious kidney dysfunction, in an otherwise healthy man taking Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP), according to a poster presented at the 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV last month in New York City. This case underlines the importance of regular kidney function monitoring while on PrEP.

alt

Read more:

Nationwide PrEP Search Engine Debuts at U.S. Conference on AIDS

Emory University and partners have developed a new web-based directory of PrEP providers across the U.S., launching the project at the U.S. Conference on AIDS taking place this week in Hollywood, Florida. The search engine can be used to help people find physicians or clinics in their area that will prescribe Truvada (tenofovir/emtricitabine) for HIV prevention.

alt

Read more:

AIDS 2016: Study Looks at Use of HIV PrEP Before and During Pregnancy and Breastfeeding

Truvada for pre-exposure prophylaxis (PrEP) when it was offered as an additional tool for preventing HIV infection during the pre-conception period, pregnancy, and breastfeeding, according to study findings presented at the 21st International AIDS Conference (AIDS 2016) last month in Durban and published in the July 19 online edition of the American Journal of Obstetrics and Gynecology.

alt

Read more:

AIDS 2016: PrEP Study Achieves High Engagement and Adherence Among Black Gay Men

What was described at the 21st International AIDS Conference (AIDS 2016) as the first PrEP trial devised and run by black gay men has shown that high levels of pre-exposure prophylaxis (PrEP) use, retention, and adherence can be achieved in a demonstration project if recruitment and support structures are tailored to the needs of black men who have sex with men.

alt

Read more:

Truvada PrEP for HIV Prevention Approved in European Union

The European Commission, which has authority over new drug in the European Union, has approved Truvada (tenofovir/emtricitabine) for HIV pre-exposure prophylaxis or PrEP, Gilead Sciences announced this week. While this marketing authorization allows Truvada for PrEP to be sold throughout the EU, regulatory authorities in each country have the final say over whether to approve it and national health systems will decide whether to offer PrEP widely and pay for it.

alt

Read more: